Events
The 2nd Annual Traumatic Brain Injury Conference
March 6-7, 2012
Washington, DC
Presentation: SyNAPSe: A Phase 3, Multi-Center Trial for Severe TBI, by Thomas MacAllister, BHR Pharma CEO
Brain Injury Awareness Day on Capitol Hill
March 21, 2012
Washington, DC
IBIA Ninth World Congress on Brain Injury
March 21-25, 2012
Edinburgh, Scotland
Poster: SyNAPSe®: Study BHR-100-301
BHR Pharma presented a poster on the SyNAPSe trial at:
NNS 2011
National Neurotrauma Society
July 11-13, 2011
Florida
Federal Interagency Conference on TBI 2011
June 13-15, 2011
Washington, DC
INTS 2011
International Neurotrauma Symposium
April 27 – May 1, 2011
Shanghai, China
AANS Annual Meeting 2011
American Association of Neurological Surgeons
April 9-13, 2011
Denver, CO
Press Releases
- September 7, 2011
BHR Pharma Meets Critical Enrollment Milestone for its SyNAPSe® Clinical Trial - March 7, 2011
BHR Pharma Sponsors 2011 Brain Injury Awareness Day - July 23, 2010
BHR Pharma Enrolls First Patient in Phase 3 SyNAPSe Traumatic Brain Injury Trial - Mar. 23, 2010
BHR Pharma Statement on Brain Injury Awareness Month - Better Awareness, Treatment, Research Needed Now - Dec. 8, 2009
BHR Pharma Files Investigational New Drug Application, Receives Orphan Drug Designation, for Traumatic Brain Injury Treatment (pdf) - Sept. 8, 2009
BHR Pharma Announces Phase 3 SyNAPSe Study of Progesterone as a Neuroprotective Agent for Traumatic Brain Injury (pdf)
In the News
- BHR Pharma Gets License for Brain Injury Treatment
Washington Business Journal, November 2009